VANCOUVER, British Columbia -- Tekmira Pharmaceuticals Corporation , a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office has recently issued two key patents: one covering its lipid nanoparticle manufacturing process and the other covering the chemical modification of siRNA to mitigate immune stimulation. (20 hours ago)
↧